Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives

Abstract Pyroptosis is a distinct form of programmed cell death characterized by the rupture of the cell membrane and robust inflammatory responses. Increasing evidence suggests that pyroptosis significantly affects the tumor microenvironment and antitumor immunity by releasing damage-associated mol...

Full description

Saved in:
Bibliographic Details
Main Authors: Chen Huang, Jiayi Li, Ruiyan Wu, Yangqian Li, Chenliang Zhang
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Molecular Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12943-025-02344-4
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850284437754871808
author Chen Huang
Jiayi Li
Ruiyan Wu
Yangqian Li
Chenliang Zhang
author_facet Chen Huang
Jiayi Li
Ruiyan Wu
Yangqian Li
Chenliang Zhang
author_sort Chen Huang
collection DOAJ
description Abstract Pyroptosis is a distinct form of programmed cell death characterized by the rupture of the cell membrane and robust inflammatory responses. Increasing evidence suggests that pyroptosis significantly affects the tumor microenvironment and antitumor immunity by releasing damage-associated molecular patterns (DAMPs) and pro-inflammatory mediators, thereby establishing it as a pivotal target in cancer immunotherapy. This review thoroughly explores the molecular mechanisms underlying pyroptosis, with a particular focus on inflammasome activation and the gasdermin family of proteins (GSDMs). It examines the role of pyroptotic cell death in reshaping the tumor immune microenvironment (TIME) involving both tumor and immune cells, and discusses recent advancements in targeting pyroptotic pathways through therapeutic strategies such as small molecule modulators, engineered nanocarriers, and combinatory treatments with immune checkpoint inhibitors. We also review recent advances and future directions in targeting pyroptosis to enhance tumor immunotherapy with immune checkpoint inhibitors, adoptive cell therapy, and tumor vaccines. This study suggested that targeting pyroptosis offers a promising avenue to amplify antitumor immune responses and surmount resistance to existing immunotherapies, potentially leading to more efficacious cancer treatments.
format Article
id doaj-art-57950c0ef7114d7484b3a2fd985fbbf2
institution OA Journals
issn 1476-4598
language English
publishDate 2025-05-01
publisher BMC
record_format Article
series Molecular Cancer
spelling doaj-art-57950c0ef7114d7484b3a2fd985fbbf22025-08-20T01:47:33ZengBMCMolecular Cancer1476-45982025-05-0124113010.1186/s12943-025-02344-4Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectivesChen Huang0Jiayi Li1Ruiyan Wu2Yangqian Li3Chenliang Zhang4Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan UniversityInstitute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan UniversityWest China Hospital, Sichuan UniversityInstitute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan UniversityDivision of Abdominal Tumor Multimodality Treatment, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan UniversityAbstract Pyroptosis is a distinct form of programmed cell death characterized by the rupture of the cell membrane and robust inflammatory responses. Increasing evidence suggests that pyroptosis significantly affects the tumor microenvironment and antitumor immunity by releasing damage-associated molecular patterns (DAMPs) and pro-inflammatory mediators, thereby establishing it as a pivotal target in cancer immunotherapy. This review thoroughly explores the molecular mechanisms underlying pyroptosis, with a particular focus on inflammasome activation and the gasdermin family of proteins (GSDMs). It examines the role of pyroptotic cell death in reshaping the tumor immune microenvironment (TIME) involving both tumor and immune cells, and discusses recent advancements in targeting pyroptotic pathways through therapeutic strategies such as small molecule modulators, engineered nanocarriers, and combinatory treatments with immune checkpoint inhibitors. We also review recent advances and future directions in targeting pyroptosis to enhance tumor immunotherapy with immune checkpoint inhibitors, adoptive cell therapy, and tumor vaccines. This study suggested that targeting pyroptosis offers a promising avenue to amplify antitumor immune responses and surmount resistance to existing immunotherapies, potentially leading to more efficacious cancer treatments.https://doi.org/10.1186/s12943-025-02344-4PyroptosisCancer immunotherapyGasderminTumor microenvironmentInflammatory cell deathImmune response
spellingShingle Chen Huang
Jiayi Li
Ruiyan Wu
Yangqian Li
Chenliang Zhang
Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives
Molecular Cancer
Pyroptosis
Cancer immunotherapy
Gasdermin
Tumor microenvironment
Inflammatory cell death
Immune response
title Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives
title_full Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives
title_fullStr Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives
title_full_unstemmed Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives
title_short Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives
title_sort targeting pyroptosis for cancer immunotherapy mechanistic insights and clinical perspectives
topic Pyroptosis
Cancer immunotherapy
Gasdermin
Tumor microenvironment
Inflammatory cell death
Immune response
url https://doi.org/10.1186/s12943-025-02344-4
work_keys_str_mv AT chenhuang targetingpyroptosisforcancerimmunotherapymechanisticinsightsandclinicalperspectives
AT jiayili targetingpyroptosisforcancerimmunotherapymechanisticinsightsandclinicalperspectives
AT ruiyanwu targetingpyroptosisforcancerimmunotherapymechanisticinsightsandclinicalperspectives
AT yangqianli targetingpyroptosisforcancerimmunotherapymechanisticinsightsandclinicalperspectives
AT chenliangzhang targetingpyroptosisforcancerimmunotherapymechanisticinsightsandclinicalperspectives